Interleukin-10 gives exhausted chimeric antigen receptor(CAR)T cells a second breath  

作　　者：Christoph Heuser-Loy 

机构地区：[1]Leibniz Institute for Immunotherapy,Division for Functional Immune Cell Modulation,Regensburg,Germany

出　　处：《Cancer Communications》2024年第7期787-790,共4页癌症通讯（英文）

基　　金：European Innovation Council and Small and Medium-sized Enterprises Executive Agency,Grant/Award Number:101070740。

摘　　要：Adoptive cell therapy(ACT)represents a major pillar of modern immuno-oncology.Naturally or synthetically endowed with the ability to recognize tumor-associated antigens,tumor-infiltrating lymphocytes(TILs)or T cells engineered to transgenically express T cell receptors or chimeric antigen receptors(CARs)are expanded and infused to tumor patients to lyse tumor cells.Yet,despite tremendous response rates against liquid tumors,many patients undergo relapses,and treatment outcomes in solid tumors have been disappointing so far[1].The harsh tumor microenvironment,including nutrient deprivation,acidification,hypoxia,and immunosuppressive signals[2,3],in conjunction with persistent antigen stimulation triggers a program of exhaustion in T cells(Figure 1A).Exhausted T cells exhibit reduced cytotoxicity and minimal proliferation potential,physiologically balancing tissue health with control of chronic viral infection or of tumor growth[4,5].Strategies to disengage or rewire the“erroneously”deployed exhaustion program to exploit the full potential of tumor-fighting T cells are highly sought after(Figure 1B).

关 键 词：INTERLEUKIN STIMULATION FIGURE 

分 类 号：R730.3[医药卫生—肿瘤]